Cure age-related macular degeneration of the retina is now possible thanks to Lucentis!
Therapy for macular retinal degeneration "The most common factor in vision loss, visual acuity in older people is the appearance of retinal degeneration," says the World Health Organization.
This is a degenerative disorder of a permanent nature that occurs in people after 55 years of age, and most often occurs in women. Medical practice divides the disease into 2 types: “wet” and “dry” degeneration.
“Dry” retinal degeneration has been progressively developing over the years and leads to a deep loss of central vision in 15-20% of those suffering from macular degeneration.
With the “wet” form, everything is much worse: it develops in a few weeks or months and occurs in 3-4 out of 10 patients.
- widely used in practice at the Moscow Eye Clinic - mgkl.ru.
The causes of the development of visual impairment can be: age-related - after 55 years, most often in women - people who suffer from cardiovascular disorders or hypertension - a long smoking habit
The nature of the disease - progressive and rapid development and changes in the retina - as a rule, absolute loss of vision throughout the year. - Clinical intervention occurs about 14 months from the time of detection of symptoms.
Manifestations and complaints at the initial stage of macular degeneration of the retina: - sharp loss of visual acuity - central scotoma - development of metamorphopsia - objects seem fuzzy - sensitivity to contrast decreases sharply
Retinal degeneration is treated to prevent the growth of a blood vessel of an abnormal origin by blocking the stimulants of the appearance of new abnormal vessels and destroying the effect on the already detected neovascular network in order to stop or prevent bleeding.
Until today, not a single method was worthy of treatment, and the disease belonged to a number of incurables. But the appearance on the medical market of Lucentis, the situation gained positive momentum. In the summer of 2006, it was approved as the only way to combat macular degeneration of the retina. The drug is able to slow the progressive development of the disease, and in some cases (if the situation with the treatment is not started) improve visual acuity. Medical institutes have developed Lucentis for use in ophthalmology. This fact gives it safety and effectiveness. Thanks to the drug, the excess stimulation of angiogenesis decreases, the net thickness returns to normal, the pathogenetic method in treatment is provided due to the effect on the growth of new vessels of active isoforms.